Browse the evidence

88% of players were categorized with low energy availability (EA) status according to the threshold of <30 kcal·kg-1 FFM.

Practitioners should address energy availability to optimize player health and performance.

Mean daily carbohydrate intake was 3.3 ± 0.7 g·kg-1 body mass.

Practitioners should ensure adequate carbohydrate intake for optimal performance.

Menopause leads to significant metabolic alterations and central and visceral fat redistribution in women.

Practitioners should be aware of the metabolic changes that occur during menopause and consider them in treatment strategies.

Changes in body composition at menopause influence risks of various health issues including cardiovascular disease and mental health disorders.

Health professionals should monitor and address the increased health risks associated with body composition changes during menopause.

Treatment of metabolic changes at menopause requires a flexible long-term strategy.

Practitioners should develop adaptable treatment plans for managing menopause-related metabolic changes.

The reductions in TG levels persisted at 26 weeks with a mean treatment difference of -12.7% compared to placebo.

ω-3-PL/FFA may provide long-term benefits in managing TG levels.

Weight gain plays an important role in the pathogenesis of obstructive sleep apnea.

Weight management strategies should be emphasized in the treatment of obstructive sleep apnea.

Tirzepatide induced a mean absolute HbA1c reduction across the three doses ranging from 2.3% to 3.0% in East Asian participants with type 2 diabetes.

Tirzepatide is effective in reducing HbA1c levels in East Asian individuals with type 2 diabetes.

SGLT-2 inhibitors and GLP-1 receptor agonists are effective in cardiovascular disease prevention among those with diabetes, heart failure, and chronic kidney disease.

Healthcare providers should consider these agents for patients with diabetes and related cardiovascular conditions.

GLP1-RA therapy appears safe and effective in patients with IBD.

GLP1-RA may be considered a treatment option for managing IBD.

GLP-1 receptor agonists have beneficial effects on atherosclerosis and cardiovascular disease.

Practitioners may consider GLP-1 receptor agonists as a treatment option for improving cardiovascular health in patients with obesity and type 2 diabetes.

MyoPS increased above REST in both untrained and trained states, with a greater increase in males.

Males may experience a greater increase in muscle protein synthesis following resistance training.

Environmental factors such as meal schedule, food contents, type of exercise, and sleep deprivation influence gut hormones and appetite.

Practitioners should consider these environmental factors when addressing appetite and weight management.

Obesity is associated with and likely has a direct causal role in the onset, progression and severity of chronic kidney disease.

Practitioners should consider the impact of obesity on chronic kidney disease management.

Obesity and chronic kidney disease place a significant burden on the health care delivery system.

Healthcare providers should be aware of the systemic impacts of obesity and CKD.

GLP-1 receptor agonists (GLP-1 RAs) may improve obstructive sleep apnea (OSA) symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation.

Practitioners may consider GLP-1 RAs as a potential treatment option for improving OSA symptoms in obese patients.

GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA.

Practitioners should consider integrating GLP-1 RAs into OSA management strategies.

GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease.

Practitioners should be aware of the potential for GLP-1 RAs to address comorbidities in obese OSA patients.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide improved physical quality of life by 3.75 points on the SF-36v2.

Semaglutide may enhance physical quality of life for patients in this group.

GLP-1RA users had a lower risk of stroke (HR, 0.81; 95% CI, 0.70-0.93) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing stroke risk in this population.

GLP-1RA users had a lower risk of all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing all-cause mortality in this population.

High school students in Philadelphia experienced reductions in soda consumption due to sugar-sweetened beverage taxes.

Implementing sugar-sweetened beverage taxes may effectively reduce soda consumption among adolescents.

Average body mass index (BMI) among high school students decreased in Philadelphia, San Francisco, and Oakland following the implementation of sugar-sweetened beverage taxes.

Sugar-sweetened beverage taxes may contribute to lower BMI in adolescents.